DRX CHOICE FIBER THERAPY- methylcellulose tablet
RARITAN PHARMACEUTICALS INC

Disclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies.

DRx Choice Fiber Therapy Methylcellulose 500 mg 100 Caplets

Active ingredient (in each caplet)

Methylcellulose (a non-allergenic fiber) 500mg

Purpose

Bulk-forming laxative

Uses

- relieves occasional constipation (irregularity)
- generally produces a bowel movement in 12 -72 hours.

Warnings

Choking: Taking this product without adequate fluid may cause it to swell and block your throat or esophagus and may cause choking .Do not take this product if you have difficulty in swallowing. If you experience chest pain, vomiting or difficulty in swallowing or breathing after taking this product, seek immediate medical attention.

Ask a doctor before use if you have

- a sudden change in bowel habits that persists over a period of two weeks
- abdominal pain, nausea or vomiting

Stop use and ask a doctor if

- constipation lasts more than 7 days
- you have rectal bleeding

These could be signs of a serious condition.

Keep out of reach of children.

In case of overdose, get medical help or contact a Poison Control Center right away at 1-800-222-1222.

Directions

Take this product (child or adult dose) with at least 8 ounces (a full glass) of water or other fluid.

- Taking this product without enough liquid may cause choking. See choking warning.

Age	Dose	Maximum Dose
adults & children 12 years of age and over	start with 2 caplets. Increase as needed up to 6 times per day.	Do not exceed 12 caplets per day
Children 6-11 years of age	Start with 1 caplet. Increase as needed up to 6 times per day	Do not exceed 6 caplets per day
children under 6 years of age	Consult a physician	Consult a physician

Other information

- **each caplet contains**: calcium 18 mg
- store at room temperature.
- protect contents from humidity
- keep tightly closed

Inactive ingredients

adipic acid, calcium carbonate, crospovidone, FD&C yellow no. 6 lake, magnesium stearate, microcrystalline cellulose, polysorbate 80, silica.

Do not use if printed seal under cap is torn or missing.

Questions or comments?

1-866-467-2748

Principal Display Panel

DRx Choice®

NDC 68163-122-00

Compare to the active Ingredients in Citrucel® Caplets *

Methylcellulose

Fiber Therapy

NatGentle and clinically proven effective†

Manufactured by:

Raritan Pharmaceuticals

8 Joanna Court,

East Brunswick, NJ 08816

†When Used as Directed

††Based On Laboratory Testing. Individual Results May Vary.

*This product is not manufactured or distributed by GlaxoSmithKline, the owner of the registered trademark Citrucel® Caplets.



DRX CHOICE FIBER THERAPY

methylcellulose tablet

Product Information			
Product Type	HUMAN OTC DRUG	**Item Code (Source)**	NDC:68163-122
Route of Administration	ORAL		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
METHYLCELLULOSE (4000 MPA.S) (UNII: MRJ667KA5E) (METHYLCELLULOSE (4000 MPA.S) - UNII:MRJ667KA5E)	METHYLCELLULOSE (4000 MPA.S)	500 mg

Inactive Ingredients

Ingredient Name	Strength
ADIPIC ACID (UNII: 76A0JE0FKJ)	
CALCIUM CARBONATE (UNII: H0G9379FGK)	
CROSPOVIDONE (120 .MU.M) (UNII: 68401960MK)	
FD&C YELLOW NO. 6 (UNII: H77VEI93A8)	
MAGNESIUM STEARATE (UNII: 70097M6I30)	
MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)	
POLYSORBATE 80 (UNII: 6OZP39ZG8H)	
SILICON DIOXIDE (UNII: ETJ7Z6XBU4)	

Product Characteristics

Color	ORANGE (Light orange)	**Score**	no score
Shape	CAPSULE (Caplet)	**Size**	19mm
Flavor		**Imprint Code**	RP122
Contains			

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:68163-122-00	100 in 1 BOTTLE; Type 0: Not a Combination Product	07/20/2022	

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
OTC monograph not final	part334	07/20/2022	

Labeler - RARITAN PHARMACEUTICALS INC (127602287)

Revised: 9/2023 RARITAN PHARMACEUTICALS INC